[Federal Register Volume 66, Number 215 (Tuesday, November 6, 2001)]
[Notices]
[Pages 56087-56088]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-27865]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Method and Compositions 
for Treating and Preventing Retinal Damage

AGENCY: Army Medical Research and Material Command, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S Patent Application No. 09/590,174 
entitled ``Method and Compositions for Treating and Preventing Retinal 
Damage'' filed June 9, 2000. Foreign rights are also available (PCT/
USOO/15812). This patent has been assigned to the United States 
Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664. Both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: This invention relates to the use of 
dihydrolipoic acid and alpha-lipoic acid to treat and prevent retinal 
damage

[[Page 56088]]

arising from physical forces such as laser beams and to compositions 
containing phenyl nitrones and dihydrolipoic acids or alpha-lipoic acid 
as neuroprotective agents. The protective effect is believed to be due 
to the metabolites ability to protect neurons by a direct antioxidant 
effect, recycling of antioxidant vitamins E and C by redox, enhancement 
of glutathione, creation of at least 8 species of free radicals, and 
enhancement of intracellular ATP. Such may be useful in glaucoma, 
temporal arteritis, macular degeneration, diabetic retinopathy, 
proliferative retinopathy, retinitis pigmentosa, and as an adjunctive 
prophylactic therapy prior to or following cataract surgery.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 01-27865 Filed 11-5-01; 8:45 am]
BILLING CODE 3710-08-M